Literature DB >> 10999436

Therapeutic effect of gypenoside on chronic liver injury and fibrosis induced by CCl4 in rats.

J C Chen1, C C Tsai, L D Chen, H H Chen, W C Wang.   

Abstract

Gypenoside is a saponins extract derived from the Gynostemma pentaphyllum. The purpose of this study was to evaluate the hepatoprotective and antifibrotic potential of Gypenoside on chronic liver injury induced by CCl4 for 8 wks. The results indicated that the increase of SGOT, SGPT activities in CCl4 liver injury were significantly reduced by treatment with Gypenoside. It also elevated the A/G ratio. For the study of anti-fibrotic potential, Gypenoside reduced the collagen content by 33%. These phenomena were confirmed by pathologic observation; thinner bands of liver collagen were found. The results suggest that Gypenoside has hepatoprotective and anti-fibrotic activities.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10999436     DOI： 10.1142/S0192415X00000222

Source DB:  PubMed          Journal:  Am J Chin Med        ISSN： 0192-415X            Impact factor:   4.667


  14 in total

1.  Gypenosides alleviate myocardial ischemia-reperfusion injury via attenuation of oxidative stress and preservation of mitochondrial function in rat heart.

Authors:  Haijie Yu; Qigang Guan; Liang Guo; Haishan Zhang; Xuefeng Pang; Ying Cheng; Xingang Zhang; Yingxian Sun
Journal:  Cell Stress Chaperones       Date:  2016-01-22       Impact factor: 3.667

2.  Arjunolic acid, a peroxisome proliferator-activated receptor α agonist, regresses cardiac fibrosis by inhibiting non-canonical TGF-β signaling.

Authors:  Trisha Bansal; Emeli Chatterjee; Jasdeep Singh; Arjun Ray; Bishwajit Kundu; V Thankamani; Shantanu Sengupta; Sagartirtha Sarkar
Journal:  J Biol Chem       Date:  2017-08-18       Impact factor: 5.157

3.  Mechanism of action of gypenosides on type 2 diabetes and non-alcoholic fatty liver disease in rats.

Authors:  Qin He; Jin-Ke Li; Fang Li; Ru-Gui Li; Guo-Qing Zhan; Gang Li; Wei-Xing Du; Hua-Bing Tan
Journal:  World J Gastroenterol       Date:  2015-02-21       Impact factor: 5.742

4.  Activation of protein serine/threonine phosphatase PP2Cα efficiently prevents liver fibrosis.

Authors:  Lirui Wang; Xu Wang; Jing Chen; Zhengyi Yang; Liang Yu; Lihong Hu; Xu Shen
Journal:  PLoS One       Date:  2010-12-06       Impact factor: 3.240

5.  Chinese medicine CGA formula ameliorates DMN-induced liver fibrosis in rats via inhibiting MMP2/9, TIMP1/2 and the TGF-β/Smad signaling pathways.

Authors:  Xue-Mei Li; Jing-Hua Peng; Zhao-Lin Sun; Hua-Jie Tian; Xiao-Hua Duan; Lin Liu; Xin Ma; Qin Feng; Ping Liu; Yi-Yang Hu
Journal:  Acta Pharmacol Sin       Date:  2016-05-02       Impact factor: 6.150

6.  Gypenoside attenuates renal ischemia/reperfusion injury in mice by inhibition of ERK signaling.

Authors:  Qifa Ye; Y I Zhu; Shaojun Ye; Hong Liu; Xingguo She; Ying Niu; Yingzi Ming
Journal:  Exp Ther Med       Date:  2016-01-29       Impact factor: 2.447

7.  Anti hyperglycemic activities of Annona muricata (Linn).

Authors:  David Olawale Adeyemi; Omobola Aderibigbe Komolafe; Olarinde Stephen Adewole; Efere Martins Obuotor; Thomas Kehinde Adenowo
Journal:  Afr J Tradit Complement Altern Med       Date:  2008-10-25

8.  Hepatoprotective effect of juglone on dimethylnitrosamine-induced liver fibrosis and its effect on hepatic antioxidant defence and the expression levels of α-SMA and collagen III.

Authors:  De-Jiang Zhou; Dong Mu; Ming-De Jiang; Shu-Mei Zheng; Yong Zhang; Sheng He; Min Weng; Wei-Zheng Zeng
Journal:  Mol Med Rep       Date:  2015-06-24       Impact factor: 2.952

9.  Metabolomic mechanisms of gypenoside against liver fibrosis in rats: An integrative analysis of proteomics and metabolomics data.

Authors:  Ya-Nan Song; Shu Dong; Bin Wei; Ping Liu; Yong-Yu Zhang; Shi-Bing Su
Journal:  PLoS One       Date:  2017-03-14       Impact factor: 3.240

10.  Gypenoside attenuates hepatic ischemia/reperfusion injury in mice via anti-oxidative and anti-apoptotic bioactivities.

Authors:  Jie Zhao; Yingzi Ming; Qiquan Wan; Shaojun Ye; Song Xie; Yi Zhu; Yanfeng Wang; Zibiao Zhong; Ling Li; Qifa Ye
Journal:  Exp Ther Med       Date:  2014-02-21       Impact factor: 2.447
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.